Tributary Capital Management’s United Therapeutics UTHR Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$433K Sell
730
-30
-4% -$14.9K 0.04% 130
2025
Q4
$370K Sell
760
-325
-30% -$151K 0.04% 142
2025
Q3
$455K Sell
1,085
-40
-4% -$13.5K 0.04% 133
2025
Q2
$323K Hold
1,125
0.03% 153
2025
Q1
$347K Buy
1,125
+375
+50% +$129K 0.03% 145
2024
Q4
$265K Sell
750
-50
-6% -$18.4K 0.02% 154
2024
Q3
$287K Hold
800
0.02% 157
2024
Q2
$255K Buy
+800
New +$212K 0.02% 160
2016
Q2
Sell
-7,400
Closed -$825K 195
2016
Q1
$825K Sell
7,400
-2,500
-25% -$316K 0.13% 159
2015
Q4
$1.55M Sell
9,900
-2,400
-20% -$349K 0.26% 123
2015
Q3
$1.61M Sell
12,300
-8,600
-41% -$1.38M 0.27% 118
2015
Q2
$3.64M Sell
20,900
-1,500
-7% -$270K 0.57% 78
2015
Q1
$3.86M Sell
22,400
-9,591
-30% -$1.46M 0.6% 75
2014
Q4
$4.14M Sell
31,991
-11,999
-27% -$1.55M 0.7% 62
2014
Q3
$5.66M Sell
43,990
-2,400
-5% -$247K 1.19% 4
2014
Q2
$4.11M Buy
46,390
+8,000
+21% +$769K 0.82% 38
2014
Q1
$3.61M Hold
38,390
0.76% 64
2013
Q4
$4.34M Sell
38,390
-209
-0.5% -$18.8K 0.86% 26
2013
Q3
$3.04M Buy
38,599
+13,748
+55% +$1M 0.63% 71
2013
Q2
$1.64M Buy
+24,851
New +$1.6M 0.27% 169

Other funds holding UTHR

Tributary Capital Management's UTHR Position: Q1 2026 in Review

Tributary Capital Management reduced its United Therapeutics (UTHR) stake by 3.9% in Q1 2026, selling an estimated $14.9K and leaving 730 shares worth $433K. The position accounts for 0.04% of the portfolio, ranked #130.

Tributary Capital Management first reported a position in UTHR in Q2 2013 and has held it in 20 quarters since. The position peaked at $5.66M in Q3 2014. 850 funds tracked by Wall St. Rank hold UTHR as of Q1 2026.

  • Tributary Capital Management held 730 shares of United Therapeutics worth $433K as of Q1 2026.
  • Tributary Capital Management sold 30 United Therapeutics shares in Q1 2026, an estimated $14.9K.
  • United Therapeutics made up 0.04% of Tributary Capital Management's portfolio in Q1 2026, its #130 holding.
  • Tributary Capital Management first reported a position in United Therapeutics in Q2 2013 and has held it in 20 quarters since.
  • Tributary Capital Management's United Therapeutics position peaked at $5.66M in Q3 2014.
  • 850 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2026.

Based on Tributary Capital Management's 13F filing for Q1 2026, filed 4 May 2026.